Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

The Secret Service shot a man near the White House on Sunday shortly after midnight after an “armed confrontation” with law enforcement, according to the agency. The encounter happened near ...

Shares in digital and delivery firms led gains during the pandemic, alongside those of vaccine-making pharmaceutical companies. Five years on, some pandemic-era gainers have lost most of their ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) reported a significant increase in cash equivalents and short-term investments, ending 2024 with $238 million compared to $170 million in 2023.

The occasion was the 2025 PRWeek Healthcare Awards, a celebration of the sector that crafts the public’s perception of pharmaceutical ... banner emblazoned with logos of corporate sponsors.

Goldman Sachs analysts removed Zealand Pharma (ZLDPF) from the firm’s European Conviction List as part of its monthly update. See what stocks are receiving Strong Buy ratings from top-rated ...

Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company’s objectives for the study Copyright ...

With a thrust on strong operations over the past decade, Indian pharma production has outpaced global growth by over two times. Image: Sanjay Rawat India’s pharmaceutical sector is at a tipping point ...

Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science companies have at least experimented with one generative AI (GenAI ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...